

Are vaccine-induced antibodies useful for phagocytosis of mastitis associated Escherichia coli?

Pierre Germon, Florence B Gilbert, Pascal Rainard

▶ To cite this version:

Pierre Germon, Florence B Gilbert, Pascal Rainard. Are vaccine-induced antibodies useful for phagocytosis of mastitis associated Escherichia coli?. 7. European Veterinary Immunology Workshop (EVIW), Aug 2021, On-line conference, France. hal-04182557

HAL Id: hal-04182557 https://hal.inrae.fr/hal-04182557v1

Submitted on 17 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



INRAe

Are vaccine-induced antibodies useful for phagocytosis of mastitis associated *Escherichia coli*?





Mastitis in numbers...

- Still a disease with significant impact
 - High prevalence
 - 30-35% of dairy cows des animaux ont une mammite au cours d'une lactation
 - High economic cost
 - Cost: 230€ per case (IDELE)
 - Overall cost: 121 to 165 € /cow (Hogeveen 2019)
 - Reduced producting lifetime (2,5 lactations per cow)
 - High antibiotic usage (70% of antibiotics in dairy farms => mastitis)
- Pathogens involved (Poutrel, 2015)
 - Clinical mastitis: Streptococcus uberis (22 %), Escherichia coli (16 %), Staphylococcus aureus (16 %)
 - Sub-clinical mastitis: Streptococcus uberis (20-30 %), S. aureus (20-30 %)



August 2021 – 7th European Veterinary Immunology Workshop


Mastitis: inflammation of the mamary gland, in general of bacterial origin



- 1. Entry of the pathogen through the teat canal
 - 2. Bacterial multiplication in milk
 - 3. Recognition of bacteria by the host immune system => inflammation
 - 4. Production of anti-microbial peptides + phagocytosis by neutrophils => bacterial clearance
- One strategy to improve bacterial clearance is vaccination to promote antibody-mediated opsonisation and increase phagocytosis by neutrophils...
- This is the rationale behind the use of the *E. coli* J5 vaccine to prevent *E. coli* mastitis




> But, given the size of an antibody and the potential protective shield provided by *E. coli* O-antigen,...



- 1. Are J5 vaccine-induced antibodies able to reach their target antigen?
- 2. Are these antibodies able to improve the phagocytosis of mastitis associated Escherichia coli?


1. Are J5 vaccine-induced antibodies able to reach their target antigen?



→ J5 vaccine-induced antibodies only weakly recognize smooth strains



2. Are antigens responsible for labeling of rough strains accessible to antibodies in smooth strains?



- → Result: Adsorption with smooth strain doens't remove antibodies recognizing


 rough strains (case #2)

 x
- → <u>Conclusion</u>: Rough strains surface antigens recognized by J5-antiserum are not accessible on smooth strains

3. Why is a small fraction of smooth strains still labelled with J5 antiserum?


Alexa Fluor 647-A


Alexa Fluor 647-A



p. 7

4. Are J5-induced antibodies improving phagocytosis by neutrophils?





→ J5-induced antibodies do not improve phagocytosis compared to pre-immune serum

5. Summary

- → J5 vaccine-induced antibodies only weakly recognize smooth strains
- → Rough strains surface antigens recognized by J5-antiserum are not accessible on smooth strains (case #2)
- ► Labeling of strain P4 by J5 antiserum is linked to labeling of type 1 fimbriae
- → J5-induced antibodies do not improve phagocytosis compared to preimmune serum

Rainard, P., M. Reperant-Ferter, C. Gitton and P. Germon (2021). Shielding Effect of *Escherichia coli* O-Antigen Polysaccharide on J5-Induced Cross-Reactive Antibodies. mSphere 6(1).

